References
- Aljefri, D. M., Avedissian, S. N., Rhodes, N. J., Postelnick, M. J., Nguyen, K., Scheetz, M. H. (2019). Vancomycin area under the curve and acute kidney injury: A meta-analysis. Clin. Infect. Diseas.,69 (11), 1881–1888.10.1093/cid/ciz051685368330715208
- Álvarez, R., Cortes, L. E. L., Molina, J., Cisneros, J. M., Pachón, J. (2016). Optimizing the clinical use of vancomycin. Antimicrob. Agents Chemother.,60 (5), 2601–2609.10.1128/AAC.03147-14486247026856841
- Bakke, V., Sporsem, H., Lippe, E., Nord¸y, I., Lao, Y., Nyrer¸d, H. C., Sandvik, L., Hårvig, K. R. (2017). Vancomycin levels are frequently subtherapeutic in critically ill patients: A prospective observational study. Acta Anaesthesiol. Scand., 61 (6), 627–635.10.1111/aas.12897548505428444760
- Baptista, J. P., Sousa, E., Martins, P. J., Pimentel, J. M. (2012). Augmented renal clearance in septic patients and implications for vancomycin optimisation. Int. J. Antimicrob. Agents, 39 (5), 420–423.10.1016/j.ijantimicag.2011.12.01122386742
- Barber, K. E., Bell, A. M., Stover, K. R., Wagner, J. L. (2016). Intravenous vancomycin dosing in the elderly: A focus on clinical issues and practical application. Drugs and Aging, 33 (12), 845–854.10.1007/s40266-016-0420-z512261827878526
- Bauer, L. A. (2008). Applied Clinical Pharmacokinetics. 2nd ed. The McGraw-Hill Companies, Inc. 826 pp.
- Campassi, M. L., Gonzalez, M. C., Masevicius, F. D., Vazquez, A. R., Moseinco, M., Navarro, N. C., Previgliano, L., Rubatto, N. P., Benites, M. H., Estenssoro, E., Dubin, A. (2014). Augmented renal clearance in critically ill patients: Incidence, associated factors and effects on vancomycin treatment. Revista Brasileira de Terapia Intensiva, 26 (1), 13–20 (in Portuguese).10.5935/0103-507X.20140003403188624770684
- Dolton, M., Xu, H., Cheong, E., Maitz, P., Kennedy, P., Gottlieb, T., Buono, E., McLachlan, A. J. (2010). Vancomycin pharmacokinetics in patients with severe burn injuries. Burns, 36 (4), 469–476.10.1016/j.burns.2009.08.01019875238
- Estes, K. S., Derendorf, H. (2010). Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecyclin, and daptomycin. Eur. J. Med. Res.,15 (12), 533.10.1186/2047-783X-15-12-533335210221163728
- Gould, F. K., Denning, D. W., Elliott, T. S., Foweraker, J., Perry, J. D., Prendergast, B. D., Sandoe, J. A. T., Spry, M. J., Watkin, R. W., Working Party of the British Society for Antimicrobial Chemotherapy (2012). Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: A report of the Working Party of the British Society for Antimicrobial Chemotherapy. J. Antimicrob. Chemother.,67 (2), 269–289.10.1093/jac/dkr45022086858
- Grace, E. (2012). Altered vancomycin pharmacokinetics in obese and morbidly obese patients: What we have learned over the past 30 years. J. Antimicrob. Chemother.,67 (6), 1305–1310.10.1093/jac/dks06622382471
- Hammond, D. A., Atkinson, L. N., James, T. B., Painter, J. T., Lusardi, K. (2017). Effects of staff education and standardizing dosing and collection times on vancomycin trough appropriateness in ward patients. Pharmacy Practice, 15 (2), 1–5.10.18549/PharmPract.2017.02.949549935528690700
- Hanberger, R. H. (2017). SEPSIS in Emergency & ICU. 3 rev. ed. LiU-Tryck, Universitetet i Linköping, Linköping. 166 pp. (in Swedish).
- Hao, J. J., Chen, H., Zhou, J. X. (2016). Continuous versus intermittent infusion of vancomycin in adult patients: A systematic review and meta-analysis. Int. J. Antimicrob. Agents, 47 (1), 28–35.10.1016/j.ijantimicag.2015.10.01926655032
- Holmes, N. E. (2020). Using AUC/MIC to guide vancomycin dosing: Ready for prime time? Clin. Microbiol. Infect.,26 (4), 406–408.10.1016/j.cmi.2019.12.02331927116
- Jeffres, M. N. (2017).The whole price of vancomycin: Toxicities, troughs, and time. Drugs, 77 (11), 1143–1154.10.1007/s40265-017-0764-7550189928573434
- Kane, S. P., Hanes, S. D. (2017). Unexplained increases in serum vancomycin concentration in a morbidly obese patient. Intens. Crit. Care Nursing, 39, 55–58.10.1016/j.iccn.2016.08.00427899248
- De Gatta Garcia, M. Del Mar F., M., Revilla, N., Calvo, M. V., Dominguez-Gil, A., Navarro, A. S. (2007). Pharmacokinetic/pharmaco-dynamic analysis of vancomycin in ICU patients. Intens. Care Med.,33 (2), 279–285.
- Marquis, K. A., DeGrado, J. R., Labonville, S., Kubiak, D. W., Szumita, P. M. (2015). Evaluation of a pharmacist-directed vancomycin dosing and monitoring pilot program at a tertiary academic medical center. Ann. Pharmacother.,49 (9), 1009–1014.10.1177/106002801558790025991831
- Martin, J. (2010). TDM for vancomycin-induced nephrotoxicity definition: A minimum of two or three consecutive. Clin. Biochem. Rev., 22, 21–24.
- McDonald, L. C., Gerding, D. N., Johnson, S., Bakken, J. S., Carroll, K. C., Coffin, S. E., Dubberke E. R., Garey, K. W., Gould, C. V., Kelly, C., Loo, V., Sammons, J. S., Sandora, T. J., Wilcox, M. H. (2018). Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin. Infect. Dis.,66 (7), e1–e48.10.1093/cid/ciy149
- Morbitzer, K. A., Jordan, J. D., Sullivan, K. A., Durr, E. A., Olm-Shipman, C. M., Rhoney, D. H. (2016). Vancomycin pharmacokinetic parameters in patients with hemorrhagic stroke. Neurocrit. Care, 25 (2), 250–257.10.1007/s12028-016-0264-826942732
- Morrison, A. P., Morrison, A. P., Melanson, S. E. F., Carty, M. G., Bates, D. W., Szumita, P. M., Tanasijevic, M. J. (2018). What proportion of vancomycin trough Levels are drawn too early? Frequency and impact on clinical actions. Amer. J. Clin. Pathol.,137 (3), 472–478.
- Raverdy, V., Ampe, E., Hecq, J.-D., Tulkens, P. M. (2013). Stability and compatibility of vancomycin for administration by continuous infusion. J. Antimicrob. Chemother.,68 (5), 1179–1182.10.1093/jac/dks51023302579
- Revilla, N., Martín-Suárez, A., Pérez, M. P., González, F. M., Fernández de Gatta, M. (2010). Vancomycin dosing assessment in intensive care unit patients based on a population pharmacokinetic/pharmacodynamic simulation. Brit. J. Clin. Pharmacol.,70 (2), 201–212.10.1111/j.1365-2125.2010.03679.x291155020653673
- Rybak, M., Lomestro, B., Rotschafer, J. C., Moellerinmg, Jr., R., Craig, W., Billeter, M., Dalovisio, J. R., Levine, D. P. (2009). Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Amer. J. Health-System Pharm.,66 (1), 82–98.10.2146/ajhp08043419106348
- Rybak, M. J. (2006). The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin. Infect. Dis., 42 (Suppl. 1), S35–S39.10.1086/49171216323118
- Rybak, M. J., Le, J., Lodise, T. P., Levine, D. P., Bradley, J. S., Liu, C., Mueller, B. A., Pai, M. P., Wong-Beringer, A., Rotschafer, J. C., Rodvold, K. A., Maples, H. D., Lomaestro, B. M. (2020).Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Amer. J. Health-System Pharm.,77 (11), 835–863.10.1093/ajhp/zxaa03632191793
- Sokolova, V., Sabelnikovs, O. (2013). Effect of vancomycin administration method on achieving and maintaining its serum concentrations in intensive care patients. Acta Chirurgica Latviensis, 13 (1), 18–21.10.2478/chilat-2014-0004
- Tabah, A., Waele, J. de, Lipman, J., Zahar, J. R., Cotta, M. O., Barton, G., Timsit, J.-F., Roberts, J. A., Working Group for Antimicrobial Use in the ICU within the Infection Section of the European Society of Intensive Care Medicine (ESICM) (2015). The ADMIN-ICU survey: A survey on antimicrobial dosing and monitoring in ICUs. J. Antimicrob. Chemother.,70 (9), 2671–2677.10.1093/jac/dkv16526169558
- Tafelski, S., Nachtigall, I., Troeger, U., Deja, M., Krannich, A., Günzel, K., Spies, C., ABx Study Group (2015) Observational clinical study on the effects of different dosing regimens on vancomycin target levels in critically ill patients: Continuous versus intermittent application. J. Infect. Publ. Health, 8 (4), 355–363.10.1016/j.jiph.2015.01.01125794497
- Tong, S. Y. C., Lye, D. C., Yahav, D., Sud, A., Robinson, J. O., Nelson, J., Archuleta, S., Roberts, M. A., Cass, A., Paterson, D. L. et al. (2020). Effect of vancomycin or daptomycin with vs without an antistaphylococcal β-lactam on mortality, bacteremia, relapse, or treatment failure in patients with MRSA bacteremia: A randomized clinical trial. J. Amer. Med. Assoc.,323 (6), 527–537.10.1001/jama.2020.0103704288732044943
- Traugott, K. A., Maxwell, P. R., Green, K., Frei, C., Lewis, J. S. 2nd (2011). Effects of therapeutic drug monitoring criteria in a computerized prescriber-order-entry system on the appropriateness of vancomycin level orders. Amer. J. Health-System Pharm.,68 (4), 347–352.10.2146/ajhp09066121289330
- Zamoner, W., Prado, I. R. S., Balbi, A. L., Ponce, D. (2019). Vancomycin dosing, monitoring and toxicity: Critical review of the clinical practice. Clin. Exper. Pharmacol. Physiol.,46 (4), 292–301.10.1111/1440-1681.1306630623980